Abstract
Although the first studies regarding the endogenous opioid system and addiction were published during the 1940s, addiction and cannabinoids were not addressed until the 1970s. Currently, the number of opioid addiction studies indexed in PubMed-Medline is 16 times greater than the number of cannabinoid addiction reports. More recently, functional interactions have been demonstrated between the endogenous cannabinoid and opioid systems. For example, the cannabinoid brain receptor type 1 (CB1) and mu opioid receptor type 1 (MOR1) co-localize in the same presynaptic nerve terminals and signal through a common receptor-mediated G-protein pathway. Here, we review a great variety of behavioral models of drug addiction and alcohol-related behaviors. We also include data providing clear evidence that activation of the cannabinoid and opioid endogenous systems via WIN 55,512-2 (0.4-10 mg/kg) and morphine (1.0-10 mg/kg), respectively, produces similar levels of relapse to alcohol in operant alcohol self-administration tasks. Finally, we discuss genetic studies that reveal significant associations between polymorphisms in MOR1 and CB1 receptors and drug addiction. For example, the SNP A118G, which changes the amino acid aspartate to asparagine in the MOR1 gene, is highly associated with altered opioid system function. The presence of a microsatellite polymorphism of an (AAT)n triplet near the CB1 gene is associated with drug addiction phenotypes. But, studies exploring haplotypes with regard to both systems, however, are lacking.
Keywords: Drug addiction, CNR1, OPRM1, alcohol, prefrontal cortex, human, rat, mouse
Current Drug Targets
Title: Functional Interactions between Endogenous Cannabinoid and Opioid Systems: Focus on Alcohol, Genetics and Drug-Addicted Behaviors
Volume: 11 Issue: 4
Author(s): J. A. Lopez-Moreno, A. Lopez-Jimenez, M. A. Gorriti and F. Rodriguez de Fonseca
Affiliation:
Keywords: Drug addiction, CNR1, OPRM1, alcohol, prefrontal cortex, human, rat, mouse
Abstract: Although the first studies regarding the endogenous opioid system and addiction were published during the 1940s, addiction and cannabinoids were not addressed until the 1970s. Currently, the number of opioid addiction studies indexed in PubMed-Medline is 16 times greater than the number of cannabinoid addiction reports. More recently, functional interactions have been demonstrated between the endogenous cannabinoid and opioid systems. For example, the cannabinoid brain receptor type 1 (CB1) and mu opioid receptor type 1 (MOR1) co-localize in the same presynaptic nerve terminals and signal through a common receptor-mediated G-protein pathway. Here, we review a great variety of behavioral models of drug addiction and alcohol-related behaviors. We also include data providing clear evidence that activation of the cannabinoid and opioid endogenous systems via WIN 55,512-2 (0.4-10 mg/kg) and morphine (1.0-10 mg/kg), respectively, produces similar levels of relapse to alcohol in operant alcohol self-administration tasks. Finally, we discuss genetic studies that reveal significant associations between polymorphisms in MOR1 and CB1 receptors and drug addiction. For example, the SNP A118G, which changes the amino acid aspartate to asparagine in the MOR1 gene, is highly associated with altered opioid system function. The presence of a microsatellite polymorphism of an (AAT)n triplet near the CB1 gene is associated with drug addiction phenotypes. But, studies exploring haplotypes with regard to both systems, however, are lacking.
Export Options
About this article
Cite this article as:
Lopez-Moreno A. J., Lopez-Jimenez A., Gorriti A. M. and de Fonseca Rodriguez F., Functional Interactions between Endogenous Cannabinoid and Opioid Systems: Focus on Alcohol, Genetics and Drug-Addicted Behaviors, Current Drug Targets 2010; 11 (4) . https://dx.doi.org/10.2174/138945010790980312
DOI https://dx.doi.org/10.2174/138945010790980312 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial: Recent Advances in Pathophysiological Studies and Treatment of Epilepsy
Current Neuropharmacology Editorial (Taking the Kidney Personally: The Quest for Novel Antigens of Idiopathic Membranous Nephropathy through Proteomic Approaches – Per Ardua Ad Astra?)
Current Pharmacogenomics and Personalized Medicine The Associations between Central Nervous System Diseases and Haemostatic Disorders
CNS & Neurological Disorders - Drug Targets Drug-Drug Interactions of Triazole Antifungal Agents in Multimorbid Patients and Implications for Patient Care
Current Drug Metabolism Palmitoylethanolamide Restores Myelinated-Fibre Function in Patients with Chemotherapy-Induced Painful Neuropathy
CNS & Neurological Disorders - Drug Targets A Review of Mechanical Seals Heat Transfer Augmentation Techniques
Recent Patents on Mechanical Engineering Synthesis and Antihypertensive Activity of Novel Quinazolin-4(3H)-one Derivatives
Central Nervous System Agents in Medicinal Chemistry Gut Microbiome: Lactation, Childbirth, Lung Dysbiosis, Animal Modeling, Stem Cell Treatment, and CNS Disorders
CNS & Neurological Disorders - Drug Targets Targeting Kinin Receptors for the Treatment of Neurological Diseases
Current Pharmaceutical Design The Impact of CRISPR/Cas9-Based Genomic Engineering on Biomedical Research and Medicine
Current Molecular Medicine Diabetes Mellitus, Hypertension and Hypercholesterolemia in Relation to the 10-Year ACS Prognosis; the GREECS Study
Current Vascular Pharmacology New Insights on Dimethylaminoethanol (DMAE) Features as a Free Radical Scavenger
Drug Metabolism Letters Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics
Current Pediatric Reviews Toxicological Effects of Dietary Biogenic Amines
Current Nutrition & Food Science Imaging the Neural Effects of Cannabinoids: Current Status and Future Opportunities for Psychopharmacology
Current Pharmaceutical Design A Review on the Prevalence of Depression in Malaysia
Current Psychiatry Reviews Cardiac Aging and Insulin Resistance: Could Insulin/Insulin-Like Growth Factor (IGF) Signaling be used as a Therapeutic Target?
Current Pharmaceutical Design Pharmacophore Modeling and Docking Studies to Investigate Potential Leads for the Development of β -Secretase APP Cleavage Enzyme-1 (BACE-1) Inhibitors
Letters in Drug Design & Discovery Chemical Exchange Saturation Transfer (CEST) Imaging of pH
Neuroscience and Biomedical Engineering (Discontinued) Treatment of Organophosphate Intoxication Using Cholinesterase Reactivators:Facts and Fiction
Mini-Reviews in Medicinal Chemistry